# Teckro > Clinical trial management software that helps life science organizations > run faster, smarter trials. Connect teams, data, and processes. Index of these documents: https://teckro.com/llms.txt ## Blog Articles (Recent) Source: https://teckro.com/resources/articles/eligibility-answered-in-minutes-not-days ### Eligibility answered in minutes, not days > How Teckro enabled a targeted communication strategy to build 87% site engagement on a difficult-to-recruit study - and resolved every site query raised. **Published:** Aug 4, 2026 **Updated:** Oct 22, 2026 --- ### Eligibility Answered in Minutes, Not Days How a targeted communication strategy built 87% site engagement on a difficult-to-recruit study - and resolved every site query raised. --- **In studies with narrow eligibility, recruitment is lost in moments.** Eligible candidates are scarce, each carries a tight window for consent and randomization, and a missed opportunity is rarely replaceable. Between candidates, the study fades from site awareness: protocol familiarity declines, inclusion criteria blur, and the study drops down the priority list at busy sites. Then a candidate appears - and the site has a question. Under a conventional operating model, that question enters an email thread. Response timing depends on inbox queues, time zones, and out-of-office coverage. The site waits. In a narrow recruitment window, waiting is often the difference between enrollment and loss. The costs of that latency are rarely itemized. They surface later, as a screening curve that lags plan and a study team weighing rescue options - by which point the moments that decided it are months in the past. Data from a Phase IIa nephrology study running across 54 registered sites shows what changes when both problems — study fade and query latency — are managed deliberately. #### A standard, built from zero ![Image]([image]) *Site Engagement by Month - Percentage of registered sites that engaged trending month on month* Every study starts at zero engagement. This one did not stay there. From activation, the study team ran a sustained, targeted communication strategy: investigator newsletters, key eligibility criteria alerts, pharmacy and lab manuals, IMP handling guidance, and local study team updates for individual markets - with open rates between 52% and 82%. Alongside that cadence, dedicated Connect query groups gave sites a direct, monitored channel for eligibility and medical questions. Engagement built month by month to a peak of 81% of registered sites, and has held at or above roughly 70% for four consecutive months. On the trailing 90-day measure, 87% of registered sites - 47 of 54 - are engaged with the study. This was not a launch spike: monthly engagement climbed for six consecutive months before settling into a sustained band in the low-to-mid 70s. Because the status is measured consistently at site level and refreshed on a regular cadence, the study team could see the standard being built - and see where it was not. **What the data shows** - Site engagement stands at 87% of registered sites on the trailing 90-day measure (47 of 54). - 56 Connect conversations were raised across seven query groups - and every one was resolved. Zero open, zero unanswered. - More than 8 in 10 of those conversations (47 of 56) were eligibility or medical queries - the questions that sit directly on the recruitment path. - In the largest group, eligibility and medical queries, time to first response was 29 minutes. The fastest groups answered in 3-4 minutes. - Sites rated the service they received at 5.0 of 5, sustained through the full communication cadence. **Connect query resolution** ![Image]([image]) Talk to us about engagement on your studies. #### The query channel is the conversion point The pattern in the queries matters as much as the speed. When sites ask about eligibility, they are holding a candidate. A first response in minutes keeps the decision inside the recruitment window; a reply measured in days frequently does not. One eligibility question on this study, raised over a holiday weekend, was answered within minutes - and the participant was consented and randomized the same day. Nothing in that exchange required new behavior from the site. It required a channel that was already open, already monitored, and already tied to the study - so the question went to people positioned to answer it, rather than to an inbox that might. The sentiment data closes the loop. A service rating of 5.0 of 5 comes from the sites actually using the channel. Sites do not rate a communication model that adds burden; they rate one that removes it. > A study run this way produces evidence rather than anecdote: which sites are present, which questions recur, where the protocol creates friction. #### From communication to execution Engagement and response time are usually treated as soft measures. Measured continuously, they become control points. Sustained engagement keeps the study present at sites between candidates - the periods when conventional oversight sees nothing. Rapid query resolution converts the moment a candidate appears. Neither shows up on a recruitment dashboard until it is too late to act on. The impact compounds. A single resolved question may secure one participant. Across a study where nearly every eligible participant matters, those moments are the recruitment curve. Across a portfolio, they change how predictably studies deliver. There is a record-keeping argument, too. A study run this way produces evidence rather than anecdote: which sites are present, which questions recur, where the protocol creates friction. Every exchange is captured in a single, auditable environment - and that record compounds across studies in a way email threads never will. #### See how Teckro turns engagement into an execution signal Connect with our experts for a personalized introduction to our solution and the data that powers it. - Request a demo --- Source: https://teckro.com/resources/articles/from-engagement-signal-to-screening-performance ### From Engagement Signal to Screening Performance > How a study using Teckro detected an engagement drop in real time, intervened within days, and moved 741 sites in 30 days. **Published:** Jul 22, 2026 **Updated:** Oct 22, 2026 --- ### From Engagement Signal to Screening Performance How one global study detected an engagement drop in real time, intervened within days, and moved 741 sites in 30 days --- **Recruitment rarely fails suddenly. It drifts. **Sites lose sight of study priorities, oversight arrives in episodes, and by the time a screening number flattens on a dashboard, months of site cost have already been spent. The problem is not that study teams lack data. It is that the data they rely on is lagging - it describes what already happened, after the window to act has closed. A recent global study shows what changes when the signal arrives earlier. #### The Signal Mid-recruitment, site engagement on the study began to trend down. On a conventional dashboard, nothing would have looked wrong for months — screening reports are retrospective, and a slowdown only becomes visible once participants fail to appear. Because engagement was measured continuously at site level, the study team saw the drop as it happened, before recruitment was lost. That distinction matters. A screening shortfall is a lagging indicator: by the time it is visible, the cost is sunk. An engagement drop is a leading indicator: it is visible while there is still time to respond. ![Image]([image]) *Site Engagement by Month - Percentage of registered sites that engaged trending month on month* #### The Intervention The study team assessed the signal and launched a targeted engagement campaign within days: weekly communications, recruitment drop-in calls, investigator newsletters, and global study updates — each linked directly to current study materials. No new systems were deployed and no additional burden was placed on sites. What changed was cadence, targeting, and relevance, directed by data. Talk to us about engagement on your studies. #### What the Data Shows ![Image]([image]) The study team plotted every activated site on two axes — engaged or not, screening or not — and compared two snapshots taken 30 days apart, constrained to the same 741 sites so the comparison holds. Within that single month: - Sites with recent engagement rose from 42% to 59% - a 17 percentage-point gain. - High performers - sites both engaged and screening - grew from 25% to 35% of the network: 75 additional sites, a 41% increase. - Low performers - neither engaged nor screening - fell from 27% to 19%. - Potential performers - engaged but not yet screening - grew from 123 to 181 sites. ![Image]([image]) Two details in that movement deserve attention. First, the growth in potential performers is not noise. Those sites were reading the protocol, opening communications, and asking questions — they had simply not yet found the right participant. On a screening-only dashboard they are indistinguishable from dead cost. In the engagement data, they are a pipeline. Second, the increased communication cadence did not fatigue sites. Site sentiment held at 4.9 of 5 across the period, with protocol sentiment at 5.0. Sites do not resent more communication. They resent irrelevant communication. #### From signal to control point Screening results tell you how a site performed last month. Engagement tells you how a site is behaving today - and on this study, the two moved together, with engagement moving first. That timing difference is the operational value. Under-engagement became visible while there was still time to intervene, the intervention could be targeted rather than broadcast, and the effect was measurable within 30 days on the same population of sites. This is the practical case for digital-first trial execution. It is not about replacing oversight or adding another system to manage. It is about giving study teams a leading indicator they can act on - so that recruitment risk is corrected in weeks, mid-study, rather than discovered at a milestone review when the options have narrowed and the cost has compounded. A single corrected drift may protect one enrollment window. Across a portfolio, it changes how predictably studies deliver. #### See how Teckro turns engagement into an execution signal Connect with our experts for a personalized introduction to our solution and the data that powers it. - Request a demo --- Source: https://teckro.com/resources/articles/engagement-leading-indicator-screening-performance ### Engagement: The leading indicator of screening performance > This Teckro case study looks at how engaged sites out-screened non-engaged sites by 28% on a study that closed screening one month ahead of schedule. **Published:** Jul 8, 2026 **Updated:** Oct 22, 2026 --- ### Engagement: The leading indicator of screening performance How engaged sites out-screened non-engaged sites by 28% on a study that closed screening one month ahead of schedule. --- **Screening rarely fails suddenly.** It drifts. Sites lose sight of study priorities, oversight arrives in episodes, and performance signals reach the study team after the window to act has closed. On most dashboards, the first hard evidence that a site is struggling is a screening number that never moves - by which point months of site cost have already been spent. Data from a global phase 2b immunology study that recruited across 358 activated sites - and closed screening one month ahead of schedule - points to an earlier, more actionable signal: engagement. #### A measurable standard, not a feeling Engagement here is not a soft concept. Every site in the network carries a clear status - engaged or not engaged with the study - measured consistently at site level and refreshed on a regular cadence. The study team sustained that engagement deliberately: milestone and screening updates on a consistent cadence, country-specific newsletters, translated study materials, and more than 90 individually targeted alerts. As of the latest data cut, 77% of activated sites were engaged. What makes the measure useful is what it predicts. > Sites that stay close to the protocol and current study guidance appear to select better candidates, not just more of them. #### What the data shows Among sites that screened at least one participant, the gap between engaged and non-engaged sites was consistent and material: - Screening closed one month ahead of schedule. - Engaged sites screened 2.18 participants per site, against 1.70 at non-engaged sites - 28% higher screening productivity. - Engaged sites accounted for 83% of all participants screened (316 of 379), and led screening in both of the study's participant cohorts - delivering 78% of one and 88% of the other. - In the sponsor's outcome analysis, engaged sites also ran a screen failure rate roughly 7 percentage points lower than non-engaged sites (46% vs. 53%) - despite screening nearly 5 times the volume. - The pattern is not a one-off. In a second study in the same program, engaged sites are screening 42% more participants per site than non-engaged sites. The screen failure result matters as much as the volume result. Screen failures are pure cost - site effort, participant burden, and budget spent with no enrollment to show for it. Sites that stay close to the protocol and current study guidance appear to select better candidates, not just more of them. Talk to us about engagement on your studies. #### One quadrant, four different solutions Plotting every activated site on two axes - engaged or not, screening or not - turns the metric into an operating model. High performers (41% of this network) are engaged and screening; they need reinforcement, not intervention. Offline performers (10%) are screening without engaging; they carry the higher screen failure rates and the weakest per-site productivity. Low performers (13%) are neither engaged nor screening - with no activity and no signal of intent, they are the true dead cost on the study, and the honest candidates for closure decisions. The fourth group is the one conventional reporting misses entirely. This study held 130 potential performers - 36% of the network - engaged but not yet screening. On a standard dashboard they are indistinguishable from the low performers: zero screens. In the engagement data they look completely different. They were reading the protocol, opening communications, educating themselves on the study - often waiting on lab equipment, working through local approvals, or holding candidates not yet seen. That is not failure. That is a pipeline. #### From communication to execution Screening results tell you how a site performed last month. Engagement tells you how a site is behaving today - and in this program, the two move together. That timing difference is the operational value: under-engagement becomes visible while there is still time to intervene, priorities can be reinforced dynamically rather than broadcast and hoped for, and resources move to the sites that need attention before the screening numbers make the problem obvious and expensive. The impact compounds. Half a participant more per engaged site, multiplied across hundreds of sites and an ongoing enrolment window, is the difference between a directed study and a rescue plan. In this study, it was worth a month. Across a portfolio, it changes how predictably studies deliver. #### See how Teckro turns engagement into an execution signal Connect with our experts for a personalized introduction to our solution and the data that powers it. - Request a demo --- Source: https://teckro.com/resources/articles/remove-delays-at-point-of-decision ### Remove delays at the point of decision > How clinical trial teams rely on Teckro to compress timelines, improve the site experience, and keep studies moving when it matters most. **Published:** May 7, 2026 **Updated:** Oct 22, 2026 --- ### Remove delays at the point of decision How digital strategies enable an interconnected approach to content and communication, maintaining patient safety and data integrity --- **Clinical trials rarely fail in obvious ways. **More often, they slow down through a series of small, avoidable delays that accumulate over time. A question goes unanswered. A response takes longer than expected. A site hesitates at a critical moment because it lacks clarity. Individually, these moments appear insignificant. Collectively, they have a direct impact on recruitment, timelines, and overall study performance. #### The moment that matters Over an Easter holiday weekend, a site in Europe identified a potential participant in a difficult-to-recruit study. The opportunity was time sensitive. Eligibility was unclear, the recruitment window was narrow, and the patient could not yet provide consent. The investigator needed a clear answer to proceed. In most trials, this type of question is handled over email. While familiar, this approach introduces friction. Responses depend on individual availability, out-of-office coverage slows coordination, and clarifications often require multiple exchanges before a decision can be made. Even short delays can be consequential. When timing is critical, the difference between a response measured in minutes rather than days can determine whether a participant is enrolled or lost. #### What changed In this case, the investigator contacted the study team through a dedicated communication channel rather than relying on email. The question was answered within minutes, confirming that the patient remained eligible. With that clarity, the site was able to continue recruitment activity without delay. Later that same day, the patient’s family was reached, consent was obtained, and the participant was successfully randomized. A time-sensitive recruitment opportunity was secured that may otherwise have been lost. > This is not simply a story about faster communication. It reflects a broader shift in how trials need to operate. #### Communication as a control point Communication is often positioned as a supporting function in clinical trials. In practice, it acts as a control point for execution. Every interaction between a site and a study team influences how the protocol is interpreted and how quickly decisions are made. When communication is fragmented across email, phone, and informal channels, there is no consistent response time, no shared visibility, and no complete record of decisions. This introduces avoidable risk into the study. This is not simply a story about faster communication. It reflects a broader shift in how trials need to operate. Sites do not require more information. They require faster access to the right information at the moment a decision needs to be made. When that access is delayed, opportunities are missed. #### A different model for faster execution A dedicated, study-specific communication channel changes how these interactions are handled. It provides direct access to study teams when questions arise, enables faster resolution of eligibility and protocol queries, and ensures that every interaction is captured within a single, auditable record. In this case, it allowed the site to move from uncertainty to decision within minutes rather than days. The impact of this approach is cumulative. A single resolved question may secure one participant, but across a study, these moments compound. Across an entire portfolio, the impact is profound. #### See how Teckro keeps studies moving when it matters most Connect with our experts for a personalized introduction to our solution and the data that powers it. - Request demo --- Source: https://teckro.com/resources/articles/from-right-thing-to-do-to-roi ### Patient Data Return: From 'right thing to do' to ROI > Why patient data return (PDR) is the critical component of a patient experience strategy that connects trust to retention in ways sponsors can see and act on. **Published:** Feb 20, 2026 **Updated:** Oct 22, 2026 --- ### Patient Data Return: From 'right thing to do' to ROI --- ##### **[Brian Deighan](#), VP of Programme Management at Teckro, argues the case for investing in the patient experience** ###### **“ROI is the elephant in the room.”** That same sentiment surfaced across several panel discussions on patient data return (PDR) at this year’s SCOPE Summit. It’s a conversation the industry has been circling for years, with a familiar refrain that tends to put PDR issues on ice. Returning data to patients is the right thing to do, so the refrain goes, but the ‘right thing to do’ isn’t what gets budgets approved. [Biogen and Teckro co-presented at SCOPE](#) on this topic – delivering individual data records to participants at scale. Across the SCOPE panels on this topic, the demand to articulate the business case was unmistakable, yet notably, [as Clinical Leader reported](#), Jane Twitchen of Biogen didn’t frame their approach around what the company stood to gain, focusing instead on strategy and execution. So what does ROI actually mean in this context? And how does something like PDR connect to the hard metrics that get budgets approved? The answer isn't as well understood as many in the industry might hope, but the good news is that with the right approach - it does connect, and it all starts with trust. ###### ![Image]([image]) Brian Deighan and Biogen's Jane Twitchen presenting at SCOPE Summit 2026 ###### The chain from trust to ROI When patients are informed about what's happening in their trial, empowered with convenient ways to participate, and feel valued as genuine partners – they're more likely to build trust and feel invested in the process. PDR is one of the most powerful ways to demonstrate that partnership. Returning individual data to participants signals recognition of both patient autonomy and their contribution to the trial, transforming a one-directional extraction into a collaboration that is both transparent and reciprocal. PDR also delivers tangible value to patients, supporting ongoing care conversations with useful, accurate data they can't get anywhere else. Once trust is established, patients are more likely to engage with the trial. Engagement is a more powerful metric than many sponsors realize – and using a digital-first approach is what transforms it into a lever for improved performance. Our data demonstrates this correlation clearly, with engaged sites recruiting significantly more patients than their less-engaged counterparts. Equipping teams with measurable, actionable engagement data is proven to accelerate timelines, with studies consistently reaching key milestones faster. In applying the same model to patients, sponsors unlock _patient retention_ – teams can track and measure patient engagement and deploy proactive, targeted interventions that keep patients engaged and on track with visits and other activities. And unlocking retention is the key to the whole business case; leading to protected timelines, reduced overall recruitment costs, and sustained participation through to study completion. When more patients stay, everything downstream improves – and when they don't, costs go up. ![Image]([image]) Sample Size = 12,887 I Base: All respondents I Source: [clinicalleader.com/doc/patient-trust-in-pharma-is-low-here-s-how-to-rebuild-it-0001](https://clinicalleader.com/doc/patient-trust-in-pharma-is-low-here-s-how-to-rebuild-it-0001) ###### The trust gap But if the chain to ROI starts with trust, how much of it does the industry actually have? Ahead of SCOPE, Clinical Leader published the first installment of a series by the Center for Information & Study on Clinical Research Participation ([CISCRP](#)) sharing findings from its [2025 Perceptions & Insights study](#). A global survey of more than 12,800 respondents, its headline finding was stark: only 18% trust pharmaceutical companies "a lot" – significantly behind research centers, healthcare providers, government research organizations, and regulatory agencies, all of which score above 40%. This isn’t a new problem. But the scale of the gap should give sponsors pause, especially when set alongside what patients actually want. [CISCRP’s own research](#) shows that 72% of patients want to see their individual study data, and 90% consider it important to receive a summary of the research results. [A pilot study published in BMJ Open](#) found that when trial data was returned to participants, 42% shared it with their healthcare providers – turning the data into something that directly improved their ongoing care. Far from being overwhelmed by data, patients are actively asking for it. Despite this, only seven out of 14 responding pharma and biotech companies currently return data to participants (according to [PHUSE’s Patient Data Return Project survey](#)). Just one has a formal policy in place. The will to act may be growing. But the gap between what patients expect and what sponsors deliver remains wide. ###### ![Image]([image]) Source: [Meaningful Approaches to Patient Engagement (CISCRP)](https://www.ciscrp.org/wp-content/uploads/2019/06/Patient-Engagement-Webinar.pdf) ###### Making the chain visible The [Clinical Leader](#) article poses that the ROI of PDR is better public trust. That's the right starting point, but as we've outlined, trust only delivers ROI when the chain from trust to engagement to retention is visible and measurable. And for many sponsors, that's been the problem. Patient experience has languished as a “nice to have” precisely because there’s been no way to see it working in real time. You can believe that a better patient experience should improve retention, but if you can’t track the connection, you can’t make the case (and you certainly can’t optimize for it). This is where a digital-first approach changes the equation. When the patient experience is delivered through a digital-first engagement model, every interaction is captured, generating an ongoing stream of behavioral data. Over time, this builds a detailed picture of how patient sentiment shifts – and where intervention can make a difference. Once this happens, engagement stops being invisible. As the link between trust and retention, it becomes an operational signal that sponsors can track and act on in real time. ###### PDR in the picture PDR is a powerful piece of this data-driven model. It reinforces trust, deepens the sense of partnership, and gives patients something tangible and meaningful for their participation. And it works best as part of a broader engagement ecosystem – one that recognizes sites as key stakeholders in the patient experience, and makes the entire journey visible and actionable for sponsors, sites, and patients alike. The value flows in both directions. Patients get a digital experience that feels responsive and meaningful, while sponsors get real-time behavioral signals that allow them to intervene proactively, support at-risk participants, and continuously improve the experience as it unfolds. Patient experience objectives and ROI outcomes stop living in silos, because they're being measured in the same framework. > Patient experience has languished as a “nice to have” precisely because there’s been no way to see it working in real time. **Where next?** The SCOPE discussions made one thing clear: the industry has moved past debating whether PDR matters. The real question is what it looks like when sponsors design the patient experience around measurable engagement from the start, and the ROI case is built into the model rather than bolted on after the fact. PDR isn’t the whole answer. But it’s a critical component of a patient experience strategy that, when built on measurable engagement, connects trust to retention in ways sponsors can actually see and act on. At Teckro, we're extending this principle from [site engagement to patient experience](#) – because the approach is the same at every level: measure engagement, act on it, improve outcomes. **_Interested in learning more? [Book a demo](#) and learn how to deliver individual data records to participants at scale._** #### How patient centricity improves engagement and retention This webinar explores how, with individual patient data return, study teams can give patients secure access to their personal medical results, supporting transparent practices, reinforcing patient trust and enabling informed onward care conversations. --- Source: https://teckro.com/resources/articles/biogen-teckro-scope-2026 ### Biogen and Teckro at SCOPE 2026: Doing the Right Thing for Patients > Join Biogen + Teckro at SCOPE 2026 for digital innovation strategies that balance evolving regulatory guidance, patient expectations, and site needs. **Published:** Nov 24, 2025 **Updated:** Oct 22, 2026 --- ### Biogen and Teckro at SCOPE 2026: Doing the Right Thing for Patients Delivering Individual Data Records to Participants at Scale. --- We’re thrilled to announce that Teckro will share the stage with Biogen at [SCOPE 2026](#) in Orlando! Join us for our joint session: ###### Doing the Right Thing: Delivering Individual Data Records to Participants at Scale Wednesday, February 4th, 8:35 AM at SCOPE 2026. ###### Speakers: - **Jane Twitchen:** Executive Director, Head Clinical Trial Accelerator Unit, Global Clinical Operations, Biogen. - **Brian Deighan:** Program Lead, Program Management, Teckro. ##### Why this matters Regulatory expectations are evolving, and patient engagement remains a central focus in clinical trials. Global regulatory bodies, and updated guidelines like ICH E6(R3), emphasize the importance of giving participants access to their clinical trial data. At the same time, patients themselves are increasingly seeking personalized study results to inform their treatment decisions. Designing trials that deliver value and meaningful insights to patients – while supporting and engaging sites – is a complex challenge. ##### What you'll learn In this session, Biogen and Teckro will explore how scalable technology can enable patient-friendly studies without compromising operational feasibility. We'll share: • Practical tools and approaches for gathering and returning individual data records • A repeatable framework that connects scientific intent with real-world delivery **• **Insights on aligning patient engagement with site efficiency This discussion is part of the [Outsourcing Track](#), under the morning theme: _The Role of Innovation and Technology in Operational Excellence._ ##### Why attend? If you’re looking for strategies that enable you to meet regulatory expectations, empower patients, and streamline site operations, this session is for you. Together, Biogen and Teckro will show how innovation can make “doing the right thing” achievable at scale. Let us know if you’re going to be at SCOPE - we’ll also be exhibiting at the event and our team would love to meet you. --- Source: https://teckro.com/resources/articles/what-if-you-could-divorce-your-printer ### What if you could divorce your printer? > A discussion on fragmented clinical research workflows and excessive use of paper, portals and passwords. **Published:** May 7, 2025 **Updated:** Oct 22, 2026 --- ### What if you could divorce your printer? A discussion on fragmented clinical research workflows and excessive use of paper, portals and passwords --- Imagine a world where the distribution, signing and filing of clinical trial documents is completed without printing a single page. A world where you have access to a comprehensive suite of study information through a single app, accessed via your mobile phone, wherever you are. An app that simplifies the management of clinical trials and facilitates more time spent on study monitoring, driving efficiencies or most importantly, patient care. Clinical trials can and should be simpler, particularly when we consider the rapid pace of the evolving industry landscape. ##### Irreconcilable Differences Industry insights tell us that most study stakeholders perceive clinical trial management as fragmented and overly complicated. Clinical trial staff face laborious paper trails, wet signature requirements, endless training acknowledgments and wholly disconnected portals. Repetition of tasks pertaining to document handling is a significant problem and a solution remains as yet, evasive. The ‘receive, read, acknowledge, print, sign, scan, save, send’ document trail is painfully familiar. What’s more, communication is often slow, manual, and inefficient. Subsequently, necessary changes are reactive and limited visibility exists for proactive decision-making. ##### Our Vision Clinical trial staff are fatigued and frustrated. At best, they have access to technology that only supports certain elements of the trial process. At worst, clinical trial staff suffer the burden of continuously navigating multiple siloed systems, paper documents, portals, passwords, and files. This results in less time fulfilling their vital role. Less time using their skillset to deliver a successful clinical trial, on time, within budget and with patients at the epicentre. At Teckro, our vision is to modernize and simplify clinical trials. Teckro wants to give time back to busy clinical trial staff by reducing the burden of documentation management and streamlining the process by which these documents advance through the trial life cycle. Providing immediate access to digitized, searchable documents at the point of care ensures more time with patients and less time sourcing portal-locked answers from other areas of the clinic. Quick, easy communication with other study members directly from a mobile phone reduces time spent waiting for answers and enables better decisions. ##### On the Horizon Teckro plans to eliminate your document management woes and become the single source of truth for your study. We want to reduce the document burden for clinical trial staff and make the paper trail more efficient and less repetitious, while maintaining compliance and inspection readiness. - Comprehensive self-service study management - Acknowledgment and sign off capabilities - Full digitization of study documents - Integrated exportable records - Robust communication and feedback loops between all study stakeholders #### A Seat at the Table That’s where you come in! We’re working hard to solve these problems and recognize the invaluable input of our users during the process. We want to supply what our industry truly needs – who can illustrate this better than our users? --- --- Source: https://teckro.com/resources/articles/how-teckro-revolutionizes-my-day-job ### How Teckro revolutionizes my day job > Clinical research coordinator Grayson Scott explains how Teckro eases the pressures on his daily working life. **Published:** May 7, 2025 **Updated:** Oct 22, 2026 --- ### How Teckro revolutionizes my day job Clinical research coordinator Grayson Scott explains how Teckro eases the pressures on his daily working life --- As a clinical research coordinator (CRC) mainly in oncology, and a site supervisor at Centricity Research, my day job can be quite demanding, to put it mildly. Being a CRC is a “boots-on-the-ground” position. As a site supervisor, I also oversee a clinic that has eight CRCs and a variety of studies. As you can imagine, there is a breadth of technology in use for each study which can be a bit overwhelming and cause extra work! For independently owned research sites, this can be extra stressful. I call this the “trickle-down” effect. While sponsors often have the best of intentions, by the time the effect of newly implemented technology gets down to the CRC, it can actually be harder to conduct tasks when the goal is always to make them simpler. To give an example with remote monitoring visits, a CRC must take documents that may be kept on paper at the site and redact patient health information before sending them electronically. It ends up being a lot of work – think manual page-by-page searching in the documents – despite the electronic systems that are supposed to be helping. ##### Instant Study Content, Even with Patients All in all, it's rather ironic that the technology that is meant to be improving workloads and saving time is more likely to be a hindrance. It doesn’t help that common sense doesn’t necessarily prevail when it comes to the technology provided. We were once forbidden from recording patient data on paper because the eDiary system was mandatory – even though it wasn’t functioning correctly. That’s just one anecdote among many I could recount demonstrating the inconsistencies and burdens site staff can experience when it comes to carrying out their daily duties. This is where I believe that Teckro really does make a difference. Teckro provides instant access to any of the essential study documents in your hand – the key things needed by a coordinator day to day, like inclusion and exclusion criteria. At Centricity we are in a “hybrid mode” so to speak. We utilize electronic regulatory processes, but paper sources. This means that all the essential documents required to conduct clinical research trials are stored electronically, but the actual patient-related data is collected mostly on paper. We are eventually moving to electronic source, but right now you’d have to print off an informed consent form if you needed it. With our essential documents (such as the study protocol) being stored electronically, Teckro makes it a breeze to review these documents. Previously, if a CRC needed to review prohibited concomitant medications, for example, they’d have to use their laptop, log in to our eRegulatory portal, and look for the protocol. With Teckro, you can just pull your phone out and search prohibited concomitant medications in the app – right there with the patient in the room. So easy! ##### Opening New Lines of Communication Not only does Teckro make my day job much easier, it also [opens lines of communication](#) between sites and sponsors. It’s rare that I would speak to a sponsor as a coordinator, but it is imperative that sponsors get site feedback. Teckro allows sites to communicate in a way that they previously wouldn't have been able to, meaning sponsors can become aware of the real issues sites are having. Teckro not only facilitates this avenue of communication, but also makes it easier to communicate on-the-job. Another advantage is the ability to negate multiple logins and URLs. As a coordinator in oncology, there are on average seven to 10 different online portals being used per study. As a coordinator, you could see 40 to 50 studies at one time – the number of URLs, passwords and usernames can be quite overwhelming. So, it’s very useful that Teckro allows us to access all content for all studies on Teckro, in one place. ##### Revolutionizing the Sponsor/Site Relationship Looking to the future, I see both regulatory and source going completely electronic in the next five to 10 years. It’s been a bit of a challenge at times so far at Centricity as we’ve gone from completely paper based – so very old school – to the cutting edge of technology. This is a huge change for an independent site. As an independent clinical research institute and network, we must do all of the leg work ourselves. If we need to implement a new piece of technology, then it is up to our own staff to learn how to use it and implement it properly. Getting the ball rolling with all this technology can be tricky, and sponsors need to work closely with sites to help build awareness and collect feedback, ensuring the solutions are helping and not hindering sites. I am positive that Teckro can help smooth the way when it comes to not only ensuring staff have instant, convenient access to the protocol to run trials more efficiently, but also by enabling better site/sponsor relationships through seamless communication. #### Meet Teckro's FAQ Copilot Imagining banishing the FAQ spreadsheet. Our FAQ Copilot transforms the way CRAs answer site questions at every stage of your study. #### Create the conditions for better study results In many other sectors, engagement functions as an operating system. Exploring a digital-first approach and how to create better user experiences, our on demand webinar considers alternatives to the service-led model in clinical trials. We discuss the impact of operationalizing engagement - powering real-time visibility of leading indicators, needs-driven site support, and proactive interventions at scale. --- Source: https://teckro.com/resources/articles/decoding-ich-e6-r3-update ### Decoding the ICH E6(R3) update > The latest Guideline for Good Clinical Practice E6(R3) from the ICH is unpacked by Kate Penn, Teckro VP, Quality Management **Published:** Apr 17, 2025 **Updated:** Oct 22, 2026 --- ### Decoding the ICH E6(R3) update GCP Guideline explained: Kate Penn, Teckro VP Quality Management, unpacks the latest changes --- _Guideline for Good Clinical Practice E6(R3) from The International Council For Harmonisation Of Technical Requirements For Pharmaceuticals For Human Use._ **** **** **With Principles and Annex 1 due to come into effect from July 2025, the ICH E6(R3) update introduces notable changes that simplify regulatory compliance and drive operational excellence in clinical research. ** By integrating digital innovation, robust risk management, and a strong emphasis on quality by design, the updated guidelines offer clear direction for enhancing oversight and efficiency throughout trial processes. ##### **Understanding the changes** Building on the General Considerations for Clinical Studies outlined in ICH E8, the ICH E6 has, for decades, provided a framework that underpins the design, conduct, recording, and reporting of clinical trials. The latest approved guidance updates this foundation with a clear mandate: application of a quality-driven and risk-proportionate approach to conducting clinical trials. Research practices must evolve to keep pace with advances in technology and scientific understanding, driving innovation that redefines trial efficiency and enhances participant safety. By embracing agile, data-driven methods and integrating cutting-edge digital solutions, the update challenges stakeholders to build clinical research systems that are as dynamic and forward-thinking as the science they support. The revised guidelines expand the scope of essential records thinking, update training requirements, and reframe communications and risk management strategies - all while ushering in a digital era of trial oversight. Key elements of the update include: - **A new role for technology:** Underscoring the role of digital innovations in clinical research, modern tools such as wearable devices, electronic data capture, and centralized digital platforms are recognized as essential for better decision-making, data oversight and agile trial management. - **Embedded risk-based monitoring and quality by design:** Reinforcing a risk-based approach to trial conduct, there is a notable emphasis on quality by design. By proactively identifying critical risks and embedding quality measures from the outset, the guidelines promote a streamlined approach that optimizes trial efficiency and ensures data reliability. - **Enhanced guidance on informed consent and data governance:** Clearer protocols for informed consent, including the use of electronic consent, are provided. Paired with more comprehensive data governance standards to safeguard data integrity throughout the trial lifecycle, this update reflects the need for improved transparency and data management in digital environments. - **Expanded collaboration among stakeholders: **ICH E6(R3) calls for broader engagement, extending collaboration beyond sponsors, investigators, and regulators to include study participants and patient advocacy groups. This approach aims to foster a more patient-centric model and better integrate diverse perspectives into clinical research. ##### **Quality by design: a reinforced focus** One of the most significant shifts in the R3 update is the explicit focus on quality by design, underscoring the importance of a well-designed trial by integrating quality standards at every stage of the trial process. By acknowledging the role of accelerating digital innovation within the industry, this update paves the way for a more data-driven, efficient, and transparent process. What does this mean in practice? - **Proactive risk management:** Instead of reacting to issues as they arise, study teams are encouraged to build robust quality measures into trial protocols from the start. - **Streamlined workflows: **By anticipating potential challenges, sponsors can design more efficient workflows that reduce trial complexity and enhance overall conduct. - **Integrated digital tools: **Modern digital platforms facilitate continuous oversight and real-time data capture, ensuring that quality measures are not an afterthought but a built-in component of trial design. This proactive approach helps to ensure that trials are compliant and adaptable in the face of evolving scientific and regulatory challenges. > ### Research practices must evolve to keep pace with advances in technology and scientific understanding, driving innovation that redefines trial efficiency and enhances participant safety. *— Kate Penn, Vice President Quality Management* ##### **Enhanced communications and document practices** The R3 update expands the trial-related communication types and ensures that significant decisions and conversations are captured, providing a comprehensive trail that supports risk review, continual improvement and regulatory compliance. The new guidelines also emphasize the importance of documenting risk assessments and broadens the communication scope of risk and mitigating activities. The change ensures that relevant stakeholders are kept informed of potential issues and the measures being taken to address them. ##### **Implications for sponsors** For sponsors and study teams, the ICH E6(R3) update is both a challenge and an opportunity. Embracing these changes means rethinking traditional approaches to study management and adopting digital tools that support proactive compliance. Modern digital platforms are uniquely positioned to help sponsors address these challenges, providing user-centric solutions that deliver dynamic data and analytics, centralized training management, and integrated communication channels. This equips sponsors to: - **Ensure compliance:** Centralized, digitized records provide a robust audit trail, simplifying the regulatory process. - **Enhance efficiency: **Streamlined workflows and fit-for-purpose communication tools reduce administrative burdens and accelerate decision-making. - **Take proactive interventions:** With more robust data and analytics oversight, study teams can identify and address issues before they impact trial outcomes. ##### **Closing thoughts** The ICH E6(R3) update represents a major overhaul of the GCP guidelines but is a forward-thinking shift in clinical research design, conduct and oversight. With a strong emphasis on quality by design, digital transformation, and seamless communications, the update challenges sponsors to adopt a more proactive, data-driven approach to study management. For organizations committed to excellence, meeting these requirements will clear the way for a more resilient, efficient, and data-centric research ecosystem, driving improved compliance and better trial performance. While the update is inherently regulatory, the underlying principles dovetail neatly with exponential advances in digital technologies. Using discernment to identify fit-for-purpose tools will equip sponsors to follow these recommendations while increasing operational efficiency and improving study outcomes. ##### **Key dates** - **January 22, 2025: **The final version of ICH E6(R3) - Principles and Annex 1 was issued. - **June 11, 2025:** ICH E6(R2) remains in effect until this date, ensuring a transition period for sponsors and stakeholders. - **July 23, 2025: **The European Medicines Agency (EMA) has set this as the legal effective date for ICH E6(R3) – Principles and Annex 1 in the EU. - **Later in 2025: **Annex II (covering non-traditional interventional trials) is expected to be adopted, with implementation projected for spring or summer 2025. ###### _For further insights on the update and digital advances in clinical research, consult [the full ICH E6(R3) guidelines](#)_ _on the ICH website._ --- Source: https://teckro.com/resources/articles/digital-first-trials-partnership-engagement-patient-data-return ### Digital-first trials: Partnership, engagement and patient data return > Forward-thinking clinical trial leaders are implementing patient-first initiatives that center data transparency. Learn why it matters. **Published:** Apr 17, 2025 **Updated:** Oct 22, 2026 --- ### Digital-first trials: Partnership, engagement and patient data return Clinical research is seeing a patient-first renaissance. --- Patient centricity has long been a guiding principle in clinical research, but for years, it remained more of an aspiration than an operational reality. Early initiatives like the James Lind Alliance (2004) and regulatory bodies such as PCORI helped embed patient perspectives into research frameworks, but the industry has struggled to translate these ideals into tangible, measurable improvements. Now, the tide is turning - not because of industry ambition alone, but because patients themselves are demanding more. They seek active participation in clinical trials, access to their data, and a clear understanding of how their contributions impact medical advancements. Many participants of modern clinical trials are not passive subjects; they are informed, digitally fluent, data-conscious stakeholders who expect a greater level of education and transparency within their patient experience, including access to their individual patient data. For sponsors, this shift represents both an opportunity and a challenge. Digital transformation and patient engagement technologies now make it possible to quantify and operationalize patient centricity, bridging the gap between intention and execution. We know poor patient experiences can lead to waning trust, lower recruitment rates, and higher dropout levels. Sponsors must examine the technological, social and ethical forces driving change, and move beyond patient-first rhetoric to prioritize meaningful patient engagement initiatives. #### Patients want to be engaged The clinical trial model was historically sponsor-driven, site-executed, and patient-included. But that hierarchy has eroded. Patients now expect - and are increasingly advocating for - a more collaborative role in clinical research. They want input on trial design and conduct and better communication channels for queries and concerns. They also want to see the resulting research data, understand it, and use it to inform their healthcare decisions: [CISCRP research](#) shows that 72% of patients voiced a strong interest in seeing their individual study data, and 90% agreed it was important to receive a summary of the research results. This challenges a long-held industry belief that patients might be overwhelmed by receiving their trial data. Regulatory discussions have evolved in response to growing demands, with a push toward patient data return (PDR) - the practice of giving participants access to their personal trial data. Once seen as a logistical or compliance challenge, PDR is now recognized as both an ethical obligation and a competitive differentiator for sponsors. Advances in digital technology solutions mean there is little validity in claims of operational, resource, or privacy constraints. A failure to provide meaningful transparency and engagement now risks alienating an increasingly informed and empowered patient base. #### The business case for patient data return Though ethics and people-first thinking rightfully inform key decisions, sponsors recognize that returning data to patients has direct, measurable business benefits far beyond altruism. When patients feel valued and informed, they are more likely to stay engaged throughout the trial - reducing costly dropout rates and improving overall study efficiency. Giving participants access to their data fosters a stronger research partnership. A pilot [study published in BMJ Open](#) found that returning both individual and aggregate trial data to participants increased patient satisfaction and that 42% shared the information with healthcare providers. This kind of transparency not only meets patient expectations but also builds long-term credibility for sponsors. Patients who feel engaged and empowered are more likely to become advocates for future participation, improving recruitment efforts in the long term. For sponsors, this is the ROI of patient-centricity: a model where transparency and engagement drive scalable study success. #### The role of user-centric technology  The shift from passive participation to active engagement is made possible by digital transformation. AI-powered tools, mobile-first study platforms, and real-time analytics are removing friction points and turning patient-centric engagement into a measurable strategy. The patient journey needs to be refined, end-to-end. A [Deloitte report](#) found that 92% of patients believe that improving experiences (such as through innovative technologies) should be a top priority. - **AI & personalization:** smart algorithms tailor study content, ensuring that patients receive relevant updates, reminders, and insights based on their trial journey. - **Mobile-first access:** patients expect on-demand access to study materials and their own data, without cumbersome portals or delayed site communications. - **Real-time engagement metrics:** sponsors no longer have to guess how engaged patients are - they can see it. Digital engagement dashboards provide insights into patient behavior, helping teams proactively address potential dropouts or disengagement. Perhaps most importantly, these digital tools don’t just benefit patients - they support sites, too. Sites with real-time study visibility and streamlined workflows are better equipped to manage patient interactions efficiently, reducing administrative burden and improving compliance. By addressing site engagement in tandem, sponsors create a foundation for sustained patient involvement - improving trial retention and optimizing recruitment strategies. Our data shows that [engaged sites perform better](#), recruiting >23% more patients than their non-engaged counterparts. #### Moving from concept to execution The industry is at an inflection point. Sponsors who move beyond high-level patient-centricity statements and implement data-driven [engagement strategies](#) will be leading the way for impactful stakeholder partnerships in clinical research. And this isn’t just theory - Transcelerate’s [participant data return initiative](#) is actively working to develop standardized best practices for returning clinical trial data to participants. This industry-wide push shows that data return is set to be more than a renewed trend. Sponsors that fail to adapt risk losing trust, facing recruitment challenges, and falling behind industry leaders already implementing these changes. #### Transforming engagement into study success At Teckro, we believe that patient-centricity is intrinsically tied to study performance, and as such, should be measurable and built around an engaging user experience. We deliver an integrated, real-time engagement ecosystem that benefits patients, sites, and sponsors. Our digital patient experience enables: - **Secure patient data return:** participants have easy access to view and share their personal trial results for better-informed onward care decisions. - **Seamless patient management:** engaged sites use streamlined workflows, reducing administrative friction and preserving time for what matters most - delivering trials. - **Real-time engagement insights:** sponsors gain visibility of patient interactions to identify trends and optimize retention strategies. **How do you measure up? ** Powered by years of site activity and study interaction data, this assessment will guide you through a series of questions to score your site engagement. --- Source: https://teckro.com/resources/articles/reframing-the-tech-burden ### Clinical trial tech: Not a volume issue > Amplifying the importance of digital, user centric, omni-channel experiences, this article challenges the industry's perspective on the "tech burden". **Published:** Apr 6, 2025 **Updated:** Oct 22, 2026 --- ### Clinical trial tech: Not a volume issue When did you last refer to “tech burden” in your personal life? --- The best consumer-facing technologies have set a standard that feels invisible; seamlessly integrated into our routines without adding friction. These solutions are built with us in mind; intuitive, mobile-first, and oriented to support whatever we are trying to achieve – across multiple devices. Compare that to [clinical trial technology](#), which is a source of annoyance for many, particularly site staff. Despite an abundance of specific tools, many day-to-day study challenges remain unresolved. The industry is flooded with poorly designed tech - countless solutions built to focus narrowly on processes instead of outcomes. These technologies consider singular problems in isolation, delivering point solutions that create disjointed workflows. They can’t support requirements for agility, real-time data, or a deeper understanding of activity on your study. Without the necessary depth, integration, and real-time insight required to make informed decisions quickly, these solutions create silos and complexity in place of efficiency. From a site perspective, things are confused. When they have questions about a trial, they often find that high CRA turnover and a [lack of in-depth protocol knowledge](#) means they have to wait for the answers needed to screen or recruit patients. They can feel forced to navigate disparate systems to resolve queries, access study documents, or even find the right person to contact – significant when every delay can impede recruitment. ###### Meeting the Demand for More Addressing these challenges requires a fresh approach. Solutions that don’t just digitize small elements of study activity, but transform how trials are conducted: - **Seamless, real-time communication:** Technology must bridge the gap between sites, sponsors, and CRAs with intuitive, responsive channels for direct and [actionable communication](#). - **Centralized engagement tools:** Solutions should integrate site queries, study documents, and actionable insights into one cohesive interface. The tools must work for sites first, providing an omni-channel, digital-first experience that enables efficient activity and fosters best-in-class engagement. - **Proactive insights over reactive data:** Instead of static reports on isolated metrics, solutions should equip study teams to capture and analyze real-time data on site activity and behavior – helping sponsors address potential issues before they impact recruitment or trial timelines. Sites are clear about what they need: Faster access to information and answers, tied to a simpler way of working.The real opportunity lies in solutions that provide direct site-to-sponsor communication, real-time answers to protocol questions, and tailored interventions based on site-specific challenges. ###### Design-First Thinking Fit-for-purpose trial technology can solve many known pain points while collecting invaluable data; driving a fundamental shift in site management practices. Prioritizing an engagement-first design, the right solutions can deliver an enhanced digital experience for sites, and granular 360° study oversight for sponsors. Better trial performance is enabled through interconnected, data-driven solutions – integrating a seamless site experience with actionable insights, and an unwavering focus on outcomes. Tools must be purpose-built not only for trial operations but for the dynamics of site engagement and performance. Challenging the status quo, this conversation invites an unflinching look at the tech currently in use, and a pragmatic assessment of whether it is working. When we place user-centric design principles at the forefront, tech volume will naturally begin to resolve downstream. Providing a purpose-built digital experience generates market-leading site engagement – the leading indicator proven to drive site performance. As the industry embraces a new standard for clinical trial technology, sponsors will be equipped to rewrite the script on trial conduct and redefine the metrics for top performing sites. In fact, sponsors partnered with Teckro have already begun. Studies that follow best practice see repeat, monthly engagement from over 70% of sites, and those sites in turn achieve a >23% higher recruitment rate. Explore our solution to learn more about the impact of a data-driven, tech-first approach. --- Source: https://teckro.com/resources/articles/embracing-life-sciences-tech-and-innovation-trends ### Building windmills: How industry leaders plan to embrace tech and innovation trends > Deloitte reports on trends and actions for 2025, with input from industry execs on digital transformation, AI and more. **Published:** Apr 6, 2025 **Updated:** Oct 22, 2026 --- ### Building windmills: How industry leaders plan to embrace tech and innovation trends Exploring key insights and perspectives from Deloitte's 2025 Life Sciences Outlook --- **_"When the winds of change blow, some people build walls and others build windmills."_** Technology advancements, regulatory updates, and a patient-centered focus are driving clinical trial design and conduct towards a period of rapid innovation. The [Deloitte 2025 Life Sciences Outlook](#) explores these trends, sharing insightful perspectives from across the industry and revealing why strategic prioritization is crucial for keeping pace and powering growth. Among 150 executives surveyed, 75% expressed optimism about the future, underscoring a focus on strategy and investment in digital innovations. Notably, 60% identified generative AI and transformative technologies as key trends to monitor closely. ##### Industry focus for 2025 Across pharmaceuticals, biotechnology and beyond, executives spoke of a focus on adaptability, creating value, and enhancing digital capabilities. The Deloitte report highlights how digital transformation and shifting customer expectations are fueling change, with planning and strategic implementation recognized as a key driver for companies to successfully differentiate. The identified trends included: **1. Technological Integration** Digital technologies are revolutionizing data management, patient engagement, and operational efficiency. From advanced analytics to AI and machine learning, companies plan to leverage these tools to streamline processes and extract insights from complex datasets. Nearly 60% of executives plan to increase generative AI investments to enhance productivity and reduce costs, with 31% investing in transformative technologies. **2. Regulatory Evolution** Regulatory frameworks are evolving to accommodate technological advancements. Adaptive trial designs and the use of real-world evidence are becoming central to accelerating approvals while maintaining patient safety and trial integrity. **3. Patient-Centricity** A renewed focus on patient experiences is reshaping trial designs. Sponsors are considering how to deliver improved patient access to information, support services, and data - before, during and after their participation in clinical trials. Personalized medicine, digital recruitment tools, and real-time feedback loops foster stronger engagement and better retention. By incorporating patient voices into protocols, sponsors can optimize outcomes while improving recruitment timelines. 36% of respondents plan to invest in enhancing customer experiences, engagement and trust. **Going to Fierce Biotech Week 2025?** So are we! Our experts will be available for meetings and to demo our data-driven site performance solution. Book a meeting in advance now. ##### Delivering Transformative Solutions Deloitte’s findings emphasize the need for solutions that improve efficiency, enhance engagement, and integrate data effectively. Teckro addresses these gaps with an interconnected, data-driven platform designed to simplify processes, empower users, and accelerate clinical trial outcomes: - **Enhanced Site Engagement: **Teckro is purpose-built to generate market-leading site engagement, driving site performance and improved study outcomes. Our solution centralizes communications, study documents, and data in one place, offering anytime study access for site staff - and critical oversight for sponsors. This empowers productivity and supports growth in high-recruiting sites, while strengthening sponsor-site relationships. Best practice studies on Teckro see repeat, monthly engagement from over 70% of sites - up to 7 times higher than traditional approaches. - **Data-Driven Performance: **Real-time analytics allow sponsors to monitor and improve site engagement - a leading indicator of performance. By combining engagement metrics with recruitment data, sponsors can segment their sites, enabling targeted performance interventions. Teckro’s predictive analytics highlight potential issues before they escalate, helping sponsors stay ahead of bottlenecks. - **Operational Efficiency: **By digitizing protocols, centralizing study communications and integrating workflows, Teckro equips sites for success and sponsors with the visibility and tools to drive improved performance. Proactive, real-time data ensures faster, better-informed responses to trial dynamics - optimizing spend, reducing time to Last Patient In (LPI) and accelerating trial timelines. #### Data-Led Trial Management Our latest webinar explores a fresh approach to measuring and managing performance - particularly with low or non-recruiting sites. Our speakers demonstrate how leading indicators of site engagement unlock value from your recruitment metrics, feeding targeted interventions that reduce time to LPI and optimize spend. ##### Leading the way Pairing a strategic approach with the right technologies will redefine how trials are conducted. The report findings show that nearly 60% of executives plan to focus on performance improvement initiatives. Teckro’s data-driven approach exemplifies the shift toward purpose-built, intuitive solutions. By focusing on seamless communication, actionable insights, and user-centric design, sponsors can foster trust with site staff while driving performance, achieving measurable ROI. Visit our features page to explore the Teckro solution, including our gen-AI enabled FAQ Copilot, premium digital experience and advanced suite of data analytics dashboards. --- Source: https://teckro.com/resources/articles/why-site-engagement-remains-study-critical ### Tufts report identifies better site support as critical to study success > A Tufts CSDD report shows site support is vital to trial success. This article explores the findings and three practical takeaways. **Published:** Apr 6, 2025 **Updated:** Oct 22, 2026 --- ### Why site engagement remains study critical Tufts report identifies better site support as critical to success. --- **_“All we are really asking for is someone committed to listening to us.” _** Clinical trial site support remains fundamentally flawed, with [research](#) from the Tufts Center for the Study of Drug Development (CSDD) indicating key challenges that continue to disrupt trial performance. [Sites feel let down by poor communication](#), generic services, and tech that is mandated for site use but not designed for them as users. This is compounded by inconsistent or delayed responses to site queries, limited access to real-time information, and a lack of CRA continuity. Broadly, site staff feel unsupported, overwhelmed, and disconnected. These challenges aren't new, but they demand new thinking. The recent findings from Tufts provide a roadmap to tackle these issues. The research identifies actionable solutions to foster sustainable engagement and improve study outcomes, based on in-depth interviews with site staff and a detailed [literature review](#). ##### Revisiting the challenges The Tufts research highlights four key barriers to effective site engagement: - **Generic support:** A one-size-fits-all approach overlooks the distinct needs of each site and hampers engagement. - **Poor communication:** Inconsistent or delayed responses to site queries disrupt productivity and impact patient enrollment opportunities. - **Inadequate technology:** Poorly designed tools overwhelm sites. Surface level integrations create fragmented workflows and unnecessary friction. - **CRA turnover:** The lack of service continuity hinders productivity, erodes trust, and leads to gaps in protocol knowledge. These issues not only delay recruitment but also strain relationships between sponsors, CROs, and sites, ultimately compromising study outcomes. Meaningful progress requires human-first solutions that center site staff needs and directly address the realities of trial conduct. ##### Actionable solutions Sponsors must focus on engaging sites and prioritize practical, human-first solutions. Here are three critical strategies: **1. Real-time communication: **Replace outdated email threads and delayed responses with instant, direct access to self-serve answers and knowledgeable points of contact. **2. Tailored interventions: **Deliver personalized support to each site, adapting resources relative to site size, experience, and current performance. **3. Site-centric digital experiences: **Guide site workflows with [integrated tools and systems](#) that centralize study information and communication, simplifying access to critical resources. #### Create the conditions for better study results In many other sectors, engagement functions as an operating system. Exploring a digital-first approach and how to create better user experiences, our on demand webinar considers alternatives to the service-led model in clinical trials. We discuss the impact of operationalizing engagement - powering real-time visibility of leading indicators, needs-driven site support, and proactive interventions at scale. ##### The shift to leading indicators Aside from the issues faced by sites, why should sponsors act? Site engagement has a [proven impact](#) on site recruitment performance, yet site staff remain largely dissatisfied and disengaged. Traditional approaches to trial conduct and site management will continue to fall short while they focus on static outputs without visibility of the inputs that drive them. Site performance is typically evaluated using metrics like recruitment numbers and retention rates. These lagging metrics fail to capture the real-time dynamics driving site success. A shift to leading indicators, such as engagement metrics, provides proactive oversight. Teckro’s platform exemplifies this approach by enabling study teams to: - **Monitor** repeat monthly engagement with critical aspects of the study - a leading indicator of site performance. - **Identify** blind spots through granular activity data, such as document access, questions raised and protocol interactions. - **Transform** low-performing sites into high performers through targeted, data-driven interventions. Case reports reveal that best practice studies see repeat monthly engagement from over 70% of their sites, accelerating recruitment and reducing time to last-patient-in by up to 20%. ##### Restoring trust through collaboration Fostering trust is essential. Sites want to feel like partners, not merely a cog in the trial machine. When sponsors and CROs listen, communicate transparently, and provide meaningful support, they create an environment where sites can thrive. As one site representative shared in the Tufts study: “Treat us as partners and treat us with respect.” A new paradigm is already emerging; with site engagement at its core. This partnership mentality requires an actionable shift to anticipating and preventing known pain points - creating a streamlined and empowering study experience that optimizes how sites interact with the trial. ##### A call to action The Tufts findings challenge the industry to reimagine how trials are conducted. Moving away from outdated practices toward purpose-built, site-centric solutions can revolutionize engagement and performance. Sponsors and CROs that embrace this focus will not only achieve faster recruitment but also build lasting relationships with their sites. Teckro’s data-driven, digital-first approach provides a proven pathway to success. By focusing on real-time communication, tailored support, and intuitive tools, Teckro empowers sites to perform at their best while delivering measurable returns for sponsors. **How do you measure up? ** Powered by years of site activity and study interaction data, this assessment will guide you through a series of questions to score your site engagement. --- Source: https://teckro.com/resources/articles/competitive-differentiation-with-ai ### Competitive differentiation with AI: Why you need a scalable strategy > To harness the potential of AI, sponsors need to address stubborn barriers, prioritize data, and embrace user-centric digital solutions. **Published:** Jan 29, 2025 **Updated:** Oct 22, 2026 --- ### Competitive differentiation with AI: Why you need a scalable strategy Exploring how industry leaders plan to harness AI and emerging technologies to drive growth, and why implementation will require strategic investment. --- Advances in data, digital transformation, and AI are poised to reshape clinical trial operations and redefine strategic priorities – if we can harness them. Recent research reveals how industry executives are approaching this shift, with 93% expecting to increase investment in these areas in 2025. Success depends on aligning these advancements with real-world needs and actionable strategies. To realize potential from their investments, sponsors need to address stubborn barriers, prioritize data, and embrace user-centric digital technology. ##### Executive insights Collated responses from leaders across biotechnology, pharma, and [life sciences](#) illustrate both the promise and the complexities of adopting generative AI and other transformative technologies, with a [survey from industry consultant ZS](#) highlighting shared views around: **1. Generative AI as a growth driver** 95% of respondents agree that AI and emerging technologies are as or more influential than traditional factors, like cost and consumer preferences, in shaping business strategy. Nearly all executives recognize AI’s potential to transition from a supporting function to a central pillar of success. **2. Tech-led strategy** This shift in focus elevates digital and AI initiatives from operational enablers to core drivers of competitive differentiation. Respondents indicate promising investments in digital, data and AI - including 48% expecting results within just 12 months in how they improve customer experiences and 35% in digital enabled trials. High-quality data and cross-functional expertise are cited as essential to balancing innovation with risk. **3. Challenges in scaling AI** While many teams have demonstrated success in generating tangible value - initiatives so far often struggle to consistently deliver results at scale. ##### Addressing the gaps Despite advancements in digital transformation, significant barriers persist. Organizations frequently grapple with fragmented systems that disrupt workflows and limit or prevent insights. Technologies that lack user-centric design fall short in meeting the needs of site staff and study teams, impacting productivity and engagement. Additionally, mounting pressure to demonstrate measurable results can lead to a focus on isolated successes rather than sustainable, scalable impact. A deeper issue lies in the disconnect between tools and the realities of clinical trials. Many platforms fail to address the nuances of site management, from communication bottlenecks to siloed data repositories. Continuing to operate without well-integrated, purpose-built solutions limits the potential of AI to support trial efficiency, streamline workflows and deliver impactful real-time data insights. - **Simplify fragmented workflow**s: Automate repetitive tasks and integrate insights within cohesive, purpose-built platforms to [enhance productivity and site engagement](https://teckro.com/resources/articles/clinical-research-site-engagement-secrets). - **Interconnect study stakeholders:** Streamline information sharing and access, and deliver best-in-class support services; funneling activity through measurable channels. - **Scale performance growth:** Leverage predictive analytics and prompt or initiate next-best actions to manage bottlenecks and resolve issues proactively. By embedding generative AI into a broader, user-centric ecosystem, sponsors can ensure strategies deliver measurable value and sustain momentum towards their goals, at a pace that is manageable for them. #### Data-Led Trial Management Our latest webinar explores a fresh approach to measuring and managing performance - particularly with low or non-recruiting sites. Our speakers demonstrate how leading indicators of site engagement unlock value from your recruitment metrics, feeding targeted interventions that reduce time to LPI and optimize spend. ##### What next? To bridge these gaps, the industry must seek solutions that are designed from the ground up to address the realities of trial conduct. AI functionality or tools should be seamlessly integrated to amplify and enhance a strong fundamental offering. The 3 key priorities for consideration are: **1. Strategic rollout** Leveraging AI effectively requires more than just implementation. Integration into enterprise-wide strategies involves not only aligning AI initiatives with organizational goals but also ensuring the availability of high-quality data to drive actionable insights. **2. Human-first implementation** User-centric design is critical. Solutions built to deliver simplicity and practicality empower site staff and study teams to navigate complex workflows with ease, reducing friction and enhancing productivity. By first prioritizing intuitive interfaces and responsive support, companies looking to benefit from AI advancements can continue to sustain engagement and trust. **3. Robust analytics** Adoption of proactive decision-making frameworks is essential. - 77% of executives have overhauled their data strategy or plan to do so - 43% report actively working on expanding their data-sharing ability - 38% plan on expanding their data-sharing ability For clinical trials, leading indicators and predictive analytics enable study teams to anticipate challenges and act decisively, minimizing delays and optimizing outcomes. When paired with AI generated insights, task handling or next steps – the impact can be exponential. ##### User-led Design Forward-thinking sponsors are already using Teckro to build data into the heart of their trial conduct models. Pioneering the only digitized, mobile-first study protocol nearly a decade ago, Teckro have long recognized the bottom-line benefit of empowered, digitally-connected sites. Our latest innovations include FAQ Copilot, an AI-enabled tool revolutionizing how CRAs manage site questions. FAQ Copilot integrates with our secure query channel, using AI to analyze site questions against approved FAQs centrally digitized in Teckro. Best-match answers are surfaced for CRAs directly within the conversation so they can immediately reply to the site using an approved response. When the study team resolve a query triaged by the CRA, our AI copilot identifies the gap and prompts the study team to generate a new FAQ from their response. With seamless, in-context review and approval, new FAQs are quickly made available for future reference – helping to reduce query escalations over time. The ZS 2025 Outlook underscores the transformative potential of AI in clinical trials. Harmonizing digital innovation with integrated, user-centric solutions will not only streamline trial operations but also pay dividends in stronger, more fruitful partnerships with their sites. Explore our recent feature releases to to see how we’re powering the digital, data-driven clinical trials of tomorrow. --- Source: https://teckro.com/resources/articles/untapped-frontline-clinical-research-data-insights ### Mining frontline insights: The untapped potential of your research staff > How sponsors can master site engagement by truly strategizing their site outreach efforts. **Published:** May 11, 2023 **Updated:** Oct 22, 2026 --- ### Mining frontline insights The untapped potential of your research staff --- Clinical trials come with a number of universal challenges. These of course evolve over time, but several recognized factors continue to impact on study success today – increasingly complex trials, capacity constraints due to high research staff turnover with fewer active investigators, and difficulties in recruiting and retaining sufficient participant numbers. Trials struggling to navigate these challenges often face significant delays, and every delay can cost millions. What’s more, they put research goals further and further out of reach. There are many industry vendors and solutions who aim to provide tools and systems that accelerate trials but in reality, often add to the complexity. We’re all familiar with site frustrations around the countless portals and passwords required per study. This oft-cited “tech burnout” is adding to the burden sites are already carrying and compounding the problem. In my experience, the most fundamental practice sponsors and study teams can adopt to tackle these challenges is to [master site engagement](#) by truly strategizing their site outreach efforts. Ultimately, the [key to clinical trial success](#) sits with study sites – investigators are the only stakeholders that can enroll patients onto a study. Connecting with investigators and other site staff in a way that adds value helps to keep a study top of mind and supports them to meet participant enrollment and retention targets. ##### Sites Have the Answers It’s essential to outline and maintain a regular, tailored communication strategy that keeps site staff both informed and updated on critical information and study progress. But how informed are most study teams about their sites? Site staff and investigators are a ready-made treasure trove of insights about a study. The best way to find out where they need support? Ask them. Directly sourcing insights or feedback from sites provides study teams with valid qualitative and quantitative data, straight from the horse’s mouth – a wealth of information that can then be used to implement meaningful changes and impactful course corrections. This includes feeding learnings gained into site outreach, such as more regular communications about a particular topic like enrollment progress or a study-wide clarification about an area of [confusion in the protocol](#). ##### Easy Surveys, Fast Insights Let’s look at an example. A study team on a Phase II oncology trial were facing recruitment challenges and had missed study milestones globally. Realizing they had a lack of awareness around site issues and pain points, they used Teckro to quickly compose a site survey and sent it to all relevant site staff across their study. They had a clear aim for the survey – to gather data on recruitment barriers and whether these were related to the inclusion/exclusion criteria. The study team received 18 responses from investigators and study coordinators across 11 countries in just 3 days. They learned: - 61% of respondents indicated tissue screening was the ultimate barrier to enrollment of potential participants. - Of those, 33% cited participant ineligibility due to PD-L1 results. - A further 28% indicated lab kit supply issues. With the ability to easily analyze incoming responses to quickly put together this picture of site recruitment barriers, the study team had the information they needed to make data-driven decisions that would support their sites. The site staff had their voices heard and contributed to a meaningful change that improved their study experience and likelihood of success – all of which helped them feel valued and more engaged. ##### More is Possible, With Teckro The power of surveying sites is clear. With Teckro, study teams can easily create and quickly share impactful site surveys themselves, instead of enduring the headache and glacial timeline of coordinating with 3rd party solutions. Sites are prompted via familiar push notifications, so chances are greater that they’ll respond. And to keep it simple, they receive and submit the survey in the same place as all other study communications, directly in the mobile app. Teckro’s survey capabilities have long enabled sponsors and study teams to seamlessly collect fast, frontline feedback from their site staff. Simple to compose with accurate, integrated audience lists and real-time read and response rates, surveys with Teckro facilitate effortless role segmentation and help to inform site outreach requirements. Even better, Teckro’s recently updated survey dashboard allows this crucial data to be maximized for optimum impact. ##### Have a Question? Ask Your Sites Teckro’s Survey dashboard now offers easy, intuitive visualization and analysis of survey results data, enabling study teams to: - Template recurring surveys: Reduce manual entry and duplication of work by saving surveys as templates to use again, securing future efficiencies and confidence in question consistency. - Visualize response data by question: Get a clear overview of answers for each survey question, making it easy to identify patterns, trends and areas for attention. - Drill into responses by site, role, country: Customize survey analyses by dynamically filtering results based on assorted criteria, helping determine whether an issue is isolated or more far-reaching and make targeted plans for improvement. This in-depth data analysis allows efficient application of learnings. Study teams can rank survey findings in order of urgency or impact to effectively triage required guidance and allocation of resources. They can determine next best steps and course-corrections for fast improvements. And they can give sites a voice, reinforcing a culture of openness and collaboration towards collective study goals. A digitally interconnected clinical trial with Teckro not only facilitates faster, easier access to a network of vital study resources and expert support, it also unlocks a world of unique, real-time data that study teams can’t get anywhere else – including an effortless way to gather insights directly from the study frontline. #### Create the conditions for better study results In many other sectors, engagement functions as an operating system. Exploring a digital-first approach and how to create better user experiences, our on demand webinar considers alternatives to the service-led model in clinical trials. We discuss the impact of operationalizing engagement - powering real-time visibility of leading indicators, needs-driven site support, and proactive interventions at scale. --- Source: https://teckro.com/resources/articles/clinical-trial-tech-frontline-research-experience ### Clinical research experience and truly useful clinical trial tech > Why harnessing the unique approach of experienced frontline clinical researchers truly addresses site staff needs. **Published:** Feb 21, 2023 **Updated:** Oct 22, 2026 --- ### Clinical research experience and truly useful clinical trial tech Why harnessing the unique approach of experienced frontline clinical researchers truly addresses site staff needs --- ##### We talk to Siobhan McKenna, Teckro Clinical Research Manager, about harnessing the unique approach of experienced frontline clinical researchers and how this translates to functionality that truly addresses site staff needs. **Can you tell us a little about your experience and why you wanted to join the team at Teckro?** My background is in nursing, and I then moved into clinical research in 2005, primarily as a study coordinator. I worked across multiple therapeutic areas and phases, including first-in-human (FIH) studies. I once remember using a platform for an HIV study that I was working on. The visits were clearly laid out, and I found it really useful and reassuring to be able to view all procedures in one place. However, there was some extra information in there that didn’t make sense for the trial. It made me think that whoever put these visits together had either never worked in clinical trials or had very little insight into what was involved. I remember thinking that it would be great to work on the tech side of the industry because I’d have the experience and knowledge required to ensure trial staff got exactly the information they needed, presented in a way that was helpful. After some research I found Teckro. I completed my master's in clinical research design in London, moved back to Ireland, and applied to join the team. I have been working at Teckro now for over five years as the clinical research manager for a team of clinical research specialists (CRS). **What are the most complex and burdensome aspects of being on the frontline of clinical research?** Ensuring that as a researcher you’re working within the realms of Good Clinical Practice (GCP) – research activities and protocol adherence are very different to working within the standard of care process. Understanding documentation and [following the protocol to the letter](#) (avoiding deviations) can be challenging, especially for more novice research staff. Referring to and accurately following long, complex schedules of assessments within a hefty protocol document, particularly on studies with multiple schedules, is just one example where researchers are at greater risk of protocol deviation. [Effective communication](#) has also always been difficult within clinical trials, in part because resource provision can be so different. For example, some sites might have one phone and computer per person and a fax/photocopier machine within easy access, whereas others might only have one phone to share across eight people, a handful of computers for everyone, and a fax/photocopier machine four floors away from where it’s needed. For busy, overwhelmed researchers, insufficient provision of communication tools hampers access to their study team, especially for support with critical decisions at the point of care. It’s worth noting that even when a site has ample phones and access to computers, traditional approaches to communication in clinical trials are slow and not always secure or compliant. **How can tech be a powerful tool for making a typical day as a clinical researcher more simple and more efficient?** [Clinical trial tech](#) should make the process easier, simpler and faster. It is broadly understood that site staff are overwhelmed by [clinical trial technology](#), often with multiple platforms, portals and passwords to use across the studies. It’s important that tech adds value and helps solve existing problems clinical researchers are facing, rather than just adding to site load. This means tech designed and built with the users in mind – something my colleague Rob talked about recently. We all use an assortment of tech and software across all aspects of our lives, and the clinical trial industry has always been a bit behind the curve on this. When clinical trial tech is fit for purpose, it can help connect study stakeholders, support protocol compliance, and enhance site engagement and performance, all while providing a positive user experience. **What does clinical research experience bring to Teckro, and why is this valuable?** The CRS team at Teckro all come from clinical research backgrounds; we have a great mix of experience across a breadth of therapeutic areas, trial phases, and multiple countries. We understand the pain points of a clinical trial and are passionate about ensuring that Teckro is optimized for each study. We’re very familiar with clinical trial documentation and resources – what they are, when they are used, and by whom. Our clinical experience means the documentation provided by each sponsor can be reviewed and validated after digitization into Teckro to ensure content integrity is preserved. We also determine the optimal format and layout of the information so that it is clear, easy to follow and logical from a researcher perspective. This same clinical research experience enables us to accurately determine the most appropriate related content to surface for any keywords or phrases searched for in the study resources. Unlike the anecdote I shared earlier of confusing and unrelated information found within a visit schedule resource, our team at Teckro has the knowledge to appropriately “map” a potential user journey through the available study information. In collaboration with sponsors, we use our collective knowledge to connect and collate appropriate selections of associated resources that a researcher might need. Teckro's user interface then harnesses this knowledge – surfacing those resources to our users working on the frontline of clinical trials. **What are some examples of how users benefit from your work?** Teckro aims to simplify clinical trials. We help reduce site staff burden by making all current, accurate study information available in one place, and accessible from a secure app on their mobile device. As this information is digitized, it’s searchable (and not like the rudimentary CTRL+F or on a PDF). When a keyword or phrase is entered, Teckro intelligently searches the entirety of study information and returns all applicable results across all available documents and resources. Furthermore, when a search result is viewed, users will also see related study content for their search term – a collation of closely associated useful information that can guide further reading and support next steps. If they still have questions, researchers can launch in-context conversations with a team of medical experts directly from within their search results, which can be answered and resolved via a secure integrated messaging channel, at the point of care. This is especially valuable for novice researchers who may not work in a highly supported environment. This “content mapping” is seen across Teckro – the schedule of activities (SoA) is accessible from the Teckro homepage, laid out in a simple, intuitive format and links directly to procedure information within the protocol, meaning researchers have access to the guidance they need, when they need it. “Quick Links” are also available on the Teckro homepage, and provide fast, easy access to the most commonly used sections of the protocol, for example inclusion/exclusion criteria, concomitant medications, adverse events. **What are your hopes for Teckro in the future?** Teckro is enabling digitally interconnected clinical trials. Each protocol in Teckro acts as a key that unlocks a breadth of resource, communication, and data touchpoints across the whole study lifecycle, benefitting all stakeholders. Ultimately, this supports study success, helping advance clinical research more broadly and get treatments to market, faster. I am enjoying seeing the continued evolution of Teckro from when I started over five years ago. I would love to see Teckro used in every trial clinic across the globe. Sites already tell us how much they love Teckro, and as we continue to grow and add more functionality to our product, I can see it being recognized as a “must have.” My team and I will always maintain our objective of ensuring that Teckro users are supported, informed and empowered, enabling them to contribute their best work to the invaluable role they play within clinical research. #### Ready to reimagine site performance? Meet with our experts for a personalized introduction to our solution and the data that powers it. --- --- Source: https://teckro.com/resources/articles/value-led-design-for-clinical-trial-technology ### Why value-led design is essential for clinical trial technology solutions > Teckro's Product Design Manager Rob Alves discusses prioritizing the needs of end users to simplify clinical trial technology. **Published:** Jan 17, 2023 **Updated:** Oct 22, 2026 --- ### Why value-led design is essential for clinical trial technology solutions Rob Alves on why it’s important for product design to be value-led --- ##### **Teckro's Product Design Manager [Rob Alves](#) discusses prioritizing the needs of end users as part of simplifying clinical trial technology.** ###### Tell us about the product design landscape? Product design is a pretty new discipline in tech companies compared to other areas. It all started with the need to create better looking interfaces, and now the main purpose is a user-focused approach to design. I've been working with design for more than 10 years now and it is interesting to see how the landscape has changed. From the famous iOS skeuomorphism design trying to mimic reality to the opposite on flat design, interfaces have been changing over the years to improve the user experience. These days, product design aims to deliver more than nice interfaces, the real focus is to solve users’ problems and address their needs. ###### What made you want to design for Teckro? Like most of the people that work here, I was drawn into the mission of modernizing clinical trials and the potential impact I could make towards improving the lives of people. While the company mission, vision and values are set from the top from our leadership team, it was clear that they filtered down into each department – understood, adopted and infused into the outputs those teams were working on delivering. I found this refreshing and it complements the way I like to approach my work. Alongside that, the team here at Teckro is exceptional, and we are all extremely excited about the work that we do. ###### What goes into designing a software product? First, we need to find out who our users are. For Teckro, this is anyone that works in the clinical trial setting, from clinical research associates and clinical research coordinators to medical monitors, principal investigators and study managers. Our users may see numerous patients day to day, supervise a dozen studies, or manage hundreds of sites. Once we know who our users are, we need to understand their needs, problems and frustrations. We regularly conduct user research and talk to as many users as possible, as well as harvesting information from the many Teckro employees who have professional clinical trial experience. This helps us build a picture to establish the areas we can offer value and ultimately make our users’ lives easier. ###### What are the design principles you work by? Teckro’s founding principles are: - **Mission: **To modernize and simplify clinical trials. - **Vision:** To engage every physician in clinical research. - **Values:** Make an impact. Do the right thing. Be responsive. Drawing on these, product design adheres to seven main design principles: 1. Start with the problem: We focus on the root cause of a problem to ensure we are providing a solution that truly addresses our users’ needs. 2. Build on research: We take time to understand our users, their problems and their environment. Using this research helps us create better products. 3. Think big, start small: We are ambitious with our vision, but realistic with our first step. We try to deliver value as quickly as we can. 4. Usability over aesthetics: Our first job is to design something that delivers value, then we make it beautiful. 5. Keep it simple: We do the hard work to make things easy. While we always strive for innovation, we also consider conventions our users are familiar with. 6. Provide clear visibility: At any given time in our product, it should be clear what has happened, what is happening, and what will happen next. 7. Work as a team: We deliver a better product when we embrace ideas from people in different disciplines and encourage constructive criticism. ###### Are there any unique factors to consider when designing software for the clinical trials industry? We always remember the high stakes involved for our users, at every level. Clinical trials are increasingly complex, with many stakeholders, and tight budgets and timelines. Our software has the potential to improve the operational success of a clinical trial – if it delivers as anticipated. Everything we do is vigorously tested and validated before being released to users. The clinical trials industry is also heavily regulated, so we need to make sure that everything we deliver is compliant. Additionally, clinical trials are tech saturated – and that’s coming from the boots on the ground researchers working on them. It’s well known that site staff are overrun with software options for their trials, often with multiple platforms per study and different platforms mandated by different sponsors. This understandably leads to frustration, dissatisfaction, and ultimately poor adoption of the technology. As a tech vendor in this space, we are mindful of the current climate at research sites and the sentiment being broadly expressed about [clinical trial technology](#). This is again where we draw on our mission and values – to ensure we offer simplicity, are responsive to need and are truly making a difference with our solution, not just adding to the problem/tech stack. ###### Why are design principles important and what is the end user benefit of product design being value driven? These principles are good practice and keep everyone aligned, but for Teckro, they’re also derived from our company ethos and values, helping to ensure these are front and center in the design process. They ensure consistency across teams and remove the need to debate simple decisions, freeing up time for us designers to focus on more complex problems., As a cohesive, value-driven team, our end users receive a product that is not only secure, compliant and extensively tested, but also simple, intuitive and created with their needs as a priority. We continually strive for growth and welcome any feedback or ideas on how we can better support our users, so they can better perform their roles in clinical research #### Create the conditions for better study results In many other sectors, engagement functions as an operating system. Exploring a digital-first approach and how to create better user experiences, our on demand webinar considers alternatives to the service-led model in clinical trials. We discuss the impact of operationalizing engagement - powering real-time visibility of leading indicators, needs-driven site support, and proactive interventions at scale. --- Source: https://teckro.com/resources/articles/multimedia-digitally-interconnected-clinical-trials ### The power of multimedia communication campaigns > Examining digital media strategies within clinical trials and how targeted study content maintains patient safety and data integrity. **Published:** Aug 9, 2022 **Updated:** Oct 22, 2026 --- ### The power of multimedia communication campaigns How digital strategies enable an interconnected approach to content and communication, maintaining patient safety and data integrity --- I've been working in digital healthcare for many years. As a product manager in the clinical trial industry, my work is driven by the broadly insufficient technical access and support that research staff have available to them on studies. This industry requires significant efficiency and quality yet is widely recognized as particularly [slow to embrace new technology](#). As a “tech-savvy” professional working in software, I'm fortunate to have my pick of problems to solve and ample tech solutions to utilize in the process. We can coordinate a feature from ideation to rollout across numerous teams, with everything tracked, current and referenceable on useful platforms and systems. Conversely, research staff on clinical trials must reckon with the full weight of the industry’s digital immaturity. [The protocol](#), bible of the trial, is a heavy tome they need to physically locate during patient appointments, usually away from clinical spaces. Questions for a CRA? Researchers wait days or longer for answers as their queries are routed through numerous, disparate channels. Current and anticipated technologies have great potential to truly accelerate the scope of clinical trial operation models. Harnessing “design thinking” to build solutions that are intuitive and user-centric removes barriers, enhances speed and safety, and improves integrity and compliance. I want to share with you what myself and the rest of the Teckro team have been working on to lead the fray in this area. ###### Digitally Interconnected Network When a clinical trial is digitally interconnected, a network of opportunity and efficiency is created. At Teckro, we know that study operations augmented with digital content and communication strategies can accelerate and streamline clinical trials – so that’s exactly what we’ve built! With our mission to modernize and simplify clinical trials, we are unique in the industry for enabling digital, searchable study content. When content is digital, it’s easily accessible on devices that users already have and are comfortable using, making the user experience intuitive and familiar. Recently, we have been focusing on advancing the cross-functionality of our platform – allowing study teams to keep pace with modern communication best practices seen in other industries. Ongoing user research and customer feedback enable our Teckro team to identify and design solutions for barriers to effective communication in clinical trials. Applying basic digital principles to both content and communication practices takes this a step further. Study teams can intertwine these elements and craft an effective, tailored communication strategy – connecting with sites and directing them to valuable, engaging content in a way they’re used to with other applications. ###### Keeping Pace = Embracing Multimedia In today’s multimedia world, video has become the leading content format. It’s widely understood that visuals are processed significantly faster than text and interpreted better. Digital strategies across many industries now prioritize video content for higher engagement, greater comprehension and overall user satisfaction. Similarly, the podcast industry is booming, with millions of users tuning in to their favorite shows every week. Multimedia content in clinical trials is largely untapped, though the benefit is clear. Consider the greater depth and clarity that can be delivered to sites by sharing a short, interesting podcast from your lead medical experts outlining the rationale for your [trial design](#). Or the intricacy that can be easily communicated. Engagement with study content is likely to translate to engagement with the study, keeping it top of mind for sites. In this way, all stakeholders reap the rewards. ###### Digital Campaigns for Effective Content Distribution Communication campaigns across various industries combine tried and tested digital strategies to improve communication efficacy and increase engagement – driving desired actions from a target audience. Increasingly, available self-service content is seeing greater consumption (even with content that has existed for years!) simply because people are being directed the right way by effective communication campaigns. But, what about the clinical research industry? With the unique application of this framework to clinical trials, those recognized strategies are translated into powerful tools for study engagement and content accessibility. Sponsors and study teams can create robust yet flexible communication plans, supplying essential information to their site staff at the right time along with driving them to associated supporting resources. When a digital approach is adopted, you can say goodbye to ineffectual email blasts! Communication no longer needs to remain static, liberating study teams to triage and meet site needs in a way that is purposeful and tailored for greater impact and greater site satisfaction. ###### Teckro: Digitally Interconnected Trials Teckro is your digital protocol, interconnecting study stakeholders with each other and the content and communication they need throughout the trial lifecycle. Our digital content and communication features work collaboratively, increasing accessibility and engagement by giving sponsors and study teams a comprehensive toolkit for connecting with their sites and monitors. Video and audio resource capability is supported, making the content – and your study – more memorable. Digital, searchable essential study documents provide self-serve answers and alleviate the paper and versioning burden. Teckro enables engaging delivery of information and study resources, on a site-by-site basis, and sites can quickly initiate conversations with study experts to ask questions or seek clarifications. Study teams and sponsors on Teckro can create targeted, tailored message templates, allowing quick and easy execution of valuable study communications. This reduces administrative burden, eliminates siloed content repositories, and helps to maintain consistency and governance of messaging. Customizable buttons can be embedded in messages, linking research staff directly to the most appropriate resource: inclusion/exclusion criteria in the protocol, a video outlining a procedure, or a question to a study expert. What’s more, engagement on Teckro is measurable, with message open rate tracking and digital content search trend data providing invaluable insights to study teams. ###### A New World of Possibility Digitally interconnected trials on Teckro surface study resources and the clinical expertise of the study team, making both available to site staff in a way that is more efficient, more powerful, and more easily consumed for simplified operations and greater study outcomes. Modern approaches are familiar and humanize your trial with content and communication that are truly helpful to your audience. Ultimately, digitally interconnected clinical trials open a new world of possibility and elevate the potential for impactful collaboration between study stakeholders. #### Ready to reimagine site performance? Meet with our experts for a personalized introduction to our solution and the data that powers it. --- --- Source: https://teckro.com/resources/articles/acrp-2022-focus-group-point-of-view ### ACRP focus group: Simplicity, support and a say > Teckro invited industry stakeholders to an ACRP 2022 focus group to discuss tech pain points on the frontline, and more. **Published:** May 19, 2022 **Updated:** Oct 22, 2026 --- ### ACRP focus group: Simplicity, support and a say An ACRP 2022 focus group discusses first-hand experiences, working wishlists and tech pain points on the frontline of clinical research. --- Most of us are aware of the danger in making assumptions. When delivering a product, best practice (and good sense) dictate no assumptions be made on how that product will be helpful to your intended consumer. Assuming you understand the pain points in a specific user community or that you know how to solve their unique issues is inherently problematic. But there is a simple way to acquire that invaluable insight – invite them to tell you. We at Teckro were lucky enough to do just that recently, with a unique, topical focus group session at ACRP 2022. ###### A Simple Circle Picture the scene: a chattering buzz fills the event space in Orlando for the returning, highly anticipated in-person ACRP conference. Among the crowd are 10 open, honest and thoughtful participants we are lucky to have joining us that morning. A simple circle of chairs awaits. There's no elaborate presentation. We don't even have desks or notebooks. What we do have is a room full of knowledgeable people, eager to share opinions, challenges and stories. Our aim is to modernize clinical trials, making life simpler for sites and other study stakeholders and in turn, supporting them to achieve successful outcomes for patients. This focus group is an opportunity for our participants to share and be heard, with us listening and learning from their valuable feedback. ###### So, What Did We Learn? The group included people from CRA, CRC and sponsor backgrounds, all of whom came together to candidly share their first-hand experiences of working on the frontline of clinical trials. These were our findings: - Sites find it difficult to be heard in clinical trial operations. The focus group itself was seen as a highly welcome opportunity for sites to have an input in industry changes and provide their feedback and suggestions - Sites can become burdened by technology without appropriate training, documentation, and troubleshooting availability from technology providers. Significant improvement in tech support and overall homogenization is needed to reduce the impact of fragmented clinical technology systems - CRCs feel their input and contribution is vastly underutilized in the process of designing protocols and amendments. They recognize ways they could help avoid future amendments, if given the opportunity to communicate early - Site staff want and need fast responses from CRAs and study teams to help them make informed decisions at the point of care - Technology must be simple and intuitive for all kinds of end users for it to be of benefit ###### Valuing User Perspective We are driven to provide solutions that clinical research teams want and need, recognizing that ongoing communication with existing and potential users is critical as we advance our offering. As well as learning more about core site challenges during the focus group, we had a chance to run ideas past key site staff on Teckro’s future vision and product roadmap, gathering invaluable insights for us to consider as we move forward. So, there you have it. To establish what qualifies as an effective solution, the most important thing we can do is consistently invite user input and provide the ongoing tech support they need to optimize their experience. Sites are ready and willing to tell us how we can make their lives simpler, negating the need for assumptions and enabling user-validated product enhancement decisions. #### Ready to reimagine site performance? Meet with our experts for a personalized introduction to our solution and the data that powers it. --- --- Source: https://teckro.com/resources/articles/clinical-research-site-engagement-secrets ### Communication: The not-so-secret secret to site engagement > Compelling industry data proving a long-held belief in effective communication being key to clinical trial success. **Published:** Apr 29, 2022 **Updated:** Oct 22, 2026 --- ### The not-so-secret secret to site engagement Effective communication is key to clinical trial success. --- Site staff are clear on the attributes they value most in sponsors, and research over recent years has revealed a central theme among respondents. In fact, the secret to site engagement is not really a secret at all, as the sentiment echoed across the top-ranked attributes conveys a collective appeal for effective communication. Those able to deliver this are one step closer to becoming Sponsors of Choice, however only half of sponsors are receiving top marks in these areas. ##### Sites have spoken [Research from Tufts CSDD](#) shows that 80% of investigative sites reported a reliance on direct communication via email with the study monitor or clinical team for protocol instructions and reported an average response time of at least 20 minutes. With the average doctor visit at just over 15 minutes, the potential for missed opportunities is clear. In 2021, the SCRS Site Landscape Survey found that 42% of site respondents intended to consider query rates and sponsor turnaround time as a key indicator in site performance measures. Recent data from the 2022 CenterWatch Report on site-ranked sponsor attributes supports this. Three of the top attributes were: - Responsive to inquiries - Maintains open communication - Staff are easily accessible for escalation of issues and provides timely and appropriate resolution ##### Communicate in a way sites hear Sites want mobile, digital communication, accessible when and where they need it, that is also: - **Relevant: **avoid bulk emails hitting overflowing inboxes. Send targeted, timely communication, applicable to their role, location or trial stage - **Responsive: **don’t ask sites to wait hours or days for answers. Accelerate query resolution by giving sites direct access to study experts at the point of care - **Centralized: **manage communication in one place, not across multiple channels. Offer simplicity and security, with notifications for time sensitive updates and guidance ##### Deliver, with Teckro Our clinical trial solution delivers what sites want and need – efficient, useful communication. The right sites receive the right message at the right time. What’s more, Teckro facilitates a powerful feedback loop – supplying you with valuable front-line perspective and giving your site staff a voice. A secure, dedicated channel empowers sites to request clarification or guidance directly from your study experts. Groups configured by topic focus the conversation, accelerating query resolution – which is also measurable. Sites are equipped with the answers they need to make better decisions at the point of care. Teckro centralizes communication – no more hunting through portals, emails, and texts. All channels are compliant, and conversations are exportable for inclusion in the TMF and ISF. Push notifications drive site engagement and study teams can track what was sent to whom and when, with open rates to measure message consumption. Sponsors of Choice know that targeted, responsive communication allows sites to make informed decisions and take confident action. We work in partnership with all study stakeholders to provide solutions that support greater site-sponsor collaboration, driving efficiencies and optimizing trial outcomes. **How do you measure up? ** Powered by years of site activity and study interaction data, this assessment will guide you through a series of questions to score your site engagement. #### Create the conditions for better study results In many other sectors, engagement functions as an operating system. Exploring a digital-first approach and how to create better user experiences, our on demand webinar considers alternatives to the service-led model in clinical trials. We discuss the impact of operationalizing engagement - powering real-time visibility of leading indicators, needs-driven site support, and proactive interventions at scale. --- *Last built: 2026-10-24*